John Robert  Wilson net worth and biography

John Wilson Biography and Net Worth

Director of AlloVir
Mr. Wilson has over 30 years of experience in the design, development and manufacture of products for the field of biotechnology, including cell culture devices and bioreactors. Mr. Wilson has obtained over 50 related patents with numerous patents currently pending. He is the co-inventor of the G-Rex® platform, which has revolutionized T cell manufacturing practices with its simple, reliable and scalable cell production. Mr. Wilson is also the co-inventor of the CELLineTM product line. Prior to co-founding Wilson Wolf Manufacturing and ViraCyte, Mr. Wilson was a principal mechanical engineer at Cellex Biosciences (now The Cell Culture Company) where he contributed to the world’s first commercially available fully-automated hollow fiber bioreactor cell culture system. Mr. Wilson has a BA in Business Administration and a BA in Economics from Hamline University in Minnesota and a B.S. in Mechanical Engineering from the University of Minnesota.

What is John Robert Wilson's net worth?

The estimated net worth of John Robert Wilson is at least $6.24 million as of March 16th, 2021. Mr. Wilson owns 7,799,350 shares of AlloVir stock worth more than $6,239,480 as of April 26th. This net worth estimate does not reflect any other assets that Mr. Wilson may own. Learn More about John Robert Wilson's net worth.

How do I contact John Robert Wilson?

The corporate mailing address for Mr. Wilson and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on John Robert Wilson's contact information.

Has John Robert Wilson been buying or selling shares of AlloVir?

John Robert Wilson has not been actively trading shares of AlloVir during the last ninety days. Most recently, John Robert Wilson sold 200,002 shares of the business's stock in a transaction on Thursday, March 11th. The shares were sold at an average price of $31.34, for a transaction totalling $6,268,062.68. Learn More on John Robert Wilson's trading history.

Who are AlloVir's active insiders?

AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.

Are insiders buying or selling shares of AlloVir?

In the last year, AlloVir insiders bought shares 1 times. They purchased a total of 2,930,870 shares worth more than $10,990,762.50. In the last year, insiders at the sold shares 44 times. They sold a total of 195,900 shares worth more than $287,187.73. The most recent insider tranaction occured on April, 22nd when CAO Brett R Hagen sold 480 shares worth more than $360.00. Insiders at AlloVir own 40.0% of the company. Learn More about insider trades at AlloVir.

Information on this page was last updated on 4/22/2024.

John Robert Wilson Insider Trading History at AlloVir

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2021Sell200,002$31.34$6,268,062.68
See Full Table

John Robert Wilson Buying and Selling Activity at AlloVir

This chart shows John Robert Wilson's buying and selling at AlloVir by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AlloVir Company Overview

AlloVir logo
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $0.80
Low: $0.76
High: $0.80

50 Day Range

MA: $0.74
Low: $0.70
High: $0.80

2 Week Range

Now: $0.80
Low: $0.62
High: $6.12

Volume

566,527 shs

Average Volume

1,166,990 shs

Market Capitalization

$91.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86